Mission Statement, Vision, & Core Values of Sangamo Therapeutics, Inc. (SGMO)

Are you curious about the driving force behind Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company? What principles guide their groundbreaking work in transforming the lives of patients? Understanding a company's mission, vision, and core values provides insight into its purpose and strategic direction. In 2024, Sangamo reported revenues of $57.8 million USD, a decrease from $0.17 billion USD in 2023, but how does this impact their commitment to their core values?

Sangamo Therapeutics, Inc. (SGMO) An Overview of

Sangamo Therapeutics, Inc. (SGMO) is a genomic medicine company focused on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene editing, cell therapy, gene therapy, and gene regulation. Founded in 1995, Sangamo has developed proprietary zinc finger nuclease (ZFN) and adeno-associated virus (AAV) technologies to enable precise and efficient modification of genes. The company's pipeline includes programs in core areas such as neurology, immunology, and metabolic diseases, as well as partnered programs addressing other disease areas. As of April 2025, Sangamo continues to advance its research and development efforts, seeking to deliver innovative therapies for diseases with significant unmet medical needs.

While specific recent sales figures as of April 2025 are not available, Sangamo's financial performance can be understood through its latest financial reports. In 2024, Sangamo Therapeutics reported total revenues of $27.7 million, a significant decrease compared to $136.7 million in 2023. This decline was primarily due to decreased collaboration agreement revenues with Kite, a Gilead Company, resulting from the completion of the KITE-037 program. Research and development expenses were $174.7 million in 2024, compared to $256.7 million in 2023. The decrease was mainly due to reduced external program costs, particularly for isaralgagene civacogene ampreloxetine, and lower personnel-related costs resulting from restructuring initiatives. General and administrative expenses totaled $61.1 million in 2024, up from $57.2 million in 2023, driven by increased professional fees and personnel-related costs. Sangamo reported a net loss of $218.2 million for 2024, compared to a net loss of $181.5 million for 2023. As of December 31, 2024, Sangamo had cash, cash equivalents, and marketable securities of $226.5 million. The company anticipates that this will fund operations into the second quarter of 2026.

Sangamo Therapeutics stands as one of the pioneering companies in the field of genomic medicine, leveraging its innovative technology platforms to develop potentially transformative therapies. The company's focus on gene editing, cell therapy, gene therapy, and gene regulation positions it at the forefront of medical innovation, addressing diseases with high unmet needs. Sangamo's strategic partnerships and internal research programs reflect its commitment to advancing the field and delivering value to patients and stakeholders.

To delve deeper into Sangamo Therapeutics, Inc. (SGMO) and understand the factors behind its success, explore: Sangamo Therapeutics, Inc. (SGMO): History, Ownership, Mission, How It Works & Makes Money

Sangamo Therapeutics, Inc. (SGMO) Mission Statement

Sangamo Therapeutics, Inc. operates with a mission focused on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives. This mission is underpinned by a commitment to innovation, the development of novel technologies, and the pursuit of cures for genetically defined diseases. Sangamo aims to develop and deliver innovative genomic therapies that address the unmet needs of patients suffering from severe conditions.

The core components of Sangamo's mission statement can be broken down into three key areas:

• Translating Ground-breaking Science: This involves converting cutting-edge research and scientific discoveries into practical and effective genomic medicines.
• Genomic Medicines with Transformative Potential: Focusing on developing therapies that have the potential to significantly improve or even cure diseases by targeting the underlying genetic causes.
• Transforming Patients’ Lives: The ultimate goal is to make a tangible, positive impact on the lives of patients and their families by providing them with new treatment options and hope for a better future.

Each of these components plays a vital role in guiding Sangamo's strategic decisions and operational activities.

Translating Ground-breaking Science

Sangamo's commitment to translating ground-breaking science is evident in its pioneering work with genomic medicines. The company leverages its expertise in areas such as zinc finger nuclease (ZFN) technology, adeno-associated virus (AAV) vectors, and cell therapy to create innovative treatment modalities. For example, Sangamo's research and development efforts have led to the development of gene editing and gene therapy approaches for various genetic diseases. This involves a deep understanding of disease biology, genetic targets, and the mechanisms by which genomic medicines can modify or correct genetic defects.

Recent advancements in gene editing technologies have significantly enhanced Sangamo's ability to precisely target and modify genes. This precision is crucial for minimizing off-target effects and maximizing the therapeutic potential of genomic medicines. The company's ongoing research focuses on refining these technologies and expanding their applications to a broader range of diseases.

Genomic Medicines with Transformative Potential

Sangamo is dedicated to developing genomic medicines that have the potential to transform the treatment landscape for genetic diseases. Unlike traditional therapies that often manage symptoms without addressing the underlying cause, genomic medicines aim to correct the genetic defects driving the disease. This approach holds the promise of providing long-lasting or even curative benefits for patients.

One example of Sangamo's transformative potential can be seen in its work with Hemophilia A, where gene therapy aims to enable patients to produce their own Factor VIII, reducing or eliminating the need for frequent infusions. According to Sangamo's 2024 report, clinical trials have demonstrated sustained Factor VIII activity in some patients, suggesting the potential for long-term disease control. These types of outcomes reflect the transformative impact genomic medicines can have on patients' lives.

Transforming Patients’ Lives

At the heart of Sangamo's mission is a deep commitment to improving the lives of patients and their families. This commitment extends beyond the development of new therapies to include a focus on patient advocacy, education, and access to treatment. Sangamo actively engages with patient communities to understand their needs and perspectives, ensuring that its research and development efforts are aligned with their priorities.

The impact of Sangamo's work is reflected not only in clinical trial results but also in the stories of patients who have benefited from its therapies. These stories serve as a constant reminder of the importance of its mission and the potential of genomic medicines to make a real difference in people's lives. As of the latest updates in 2024, Sangamo continues to prioritize patient-centric approaches in its clinical development programs, aiming to deliver therapies that not only address the medical needs of patients but also improve their overall quality of life.

For more insights into Sangamo Therapeutics, Inc., explore Exploring Sangamo Therapeutics, Inc. (SGMO) Investor Profile: Who’s Buying and Why?

Sangamo Therapeutics, Inc. (SGMO) Vision Statement of

To fully understand Sangamo Therapeutics, Inc. (SGMO), it is essential to examine its mission, vision, and core values. These elements provide a clear picture of the company's goals, aspirations, and the principles that guide its operations. The vision reflects the company's long-term objectives and desired future state. The mission defines its current purpose and how it aims to achieve its vision. The core values outline the ethical and operational guidelines that shape the company's culture and behavior. Together, these components form the foundation of Sangamo Therapeutics, offering insight into its strategic direction and commitment to its stakeholders. For a deeper dive into Sangamo's history, mission, ownership, and operational details, you can explore this resource: Sangamo Therapeutics, Inc. (SGMO): History, Ownership, Mission, How It Works & Makes Money.

Sangamo Therapeutics' mission is to translate ground-breaking science into genomic medicines with the potential to transform patients’ lives.

Key aspects of Sangamo's mission statement include:

• Ground-breaking Science: Sangamo focuses on innovative research and development in the field of genomic medicine.
• Genomic Medicines: The company is dedicated to creating therapies that address diseases at the genetic level.
• Transforming Patients’ Lives: The ultimate goal is to develop treatments that significantly improve the health and well-being of patients.

Sangamo Therapeutics envisions a future where genomic medicine transforms the lives of patients with currently incurable diseases.

Analyzing the vision statement:

• Future Focus: The vision looks ahead to a time when genomic medicine is widely accessible and effective.
• Transformative Impact: The company aims to revolutionize the treatment of diseases that are currently difficult or impossible to cure.
• Patient-Centric: The primary focus is on improving the lives and outcomes for patients suffering from serious illnesses.

Sangamo Therapeutics' core values are centered around innovation, collaboration, and dedication to patients. These values drive their approach to research, development, and corporate responsibility.

The core values are reflected in their actions:

• Innovation: Sangamo is committed to pushing the boundaries of science and technology to develop novel genomic medicines.
• Collaboration: The company fosters partnerships and teamwork to leverage diverse expertise and resources.
• Dedication to Patients: Sangamo prioritizes the needs of patients, ensuring that their well-being is at the heart of every decision.

Sangamo Therapeutics, Inc. (SGMO) Core Values of

Sangamo Therapeutics, Inc. is dedicated to translating groundbreaking science into genomic medicines with the potential to transform patients’ lives. The company’s mission is reflected in its core values, which guide its operations, decisions, and interactions with stakeholders.

Pioneering Innovation

Sangamo emphasizes pioneering innovation as a core value, driving its efforts to develop novel genomic medicines. This commitment is evident in their research and development activities, which focus on addressing unmet medical needs through innovative technological platforms. For example, Sangamo's work in gene editing and gene therapy showcases its dedication to pushing the boundaries of science to create potentially curative treatments. As of the fiscal year 2024, Sangamo invested a significant portion of its resources, with research and development expenses totaling $243.7 million, underscoring its focus on innovation. This figure represents a substantial commitment to advancing its pipeline and technologies.

Commitment to Patients

A core value of Sangamo is its unwavering commitment to patients. This dedication is exemplified through patient-centric drug development, clinical trial design, and patient advocacy efforts. Sangamo strives to ensure that patient needs are at the forefront of its activities, from early research to commercialization. For instance, Sangamo actively engages with patient communities to understand their experiences and incorporate their feedback into the development process. In 2024, Sangamo continued to advance clinical programs for diseases with limited treatment options, reflecting its commitment to addressing unmet needs. This patient-focused approach is central to Sangamo’s mission of transforming lives through genomic medicines. You can learn more about Sangamo's financial health and investment insights at: Breaking Down Sangamo Therapeutics, Inc. (SGMO) Financial Health: Key Insights for Investors

Integrity and Ethics

Sangamo places a high value on integrity and ethics in all its operations. This commitment is demonstrated through adherence to rigorous ethical standards, transparency in communication, and accountability in decision-making. Sangamo maintains a strong compliance program to ensure that its activities meet the highest legal and ethical requirements. For example, Sangamo's code of conduct emphasizes honesty, respect, and fairness in all interactions. In 2024, Sangamo continued to uphold these standards, reinforcing its reputation as a responsible corporate citizen. This commitment to integrity is crucial for maintaining trust with patients, partners, and the broader community.

Collaboration and Partnership

Sangamo recognizes the importance of collaboration and partnership in achieving its goals. This value is reflected in its strategic alliances with other companies, academic institutions, and patient organizations. Sangamo actively seeks opportunities to leverage external expertise and resources to accelerate the development of its genomic medicines. For instance, Sangamo has established partnerships with leading pharmaceutical companies to advance its pipeline programs. In 2024, Sangamo continued to foster collaborative relationships, which are essential for driving innovation and expanding its reach. These partnerships enable Sangamo to combine its expertise with that of others, maximizing the potential to deliver transformative therapies to patients.

Employee Development and Inclusion

Sangamo values its employees and is committed to fostering a diverse and inclusive workplace. This commitment is demonstrated through programs that support employee development, promote work-life balance, and encourage diversity and inclusion. Sangamo strives to create an environment where all employees feel valued, respected, and empowered to contribute their best. For example, Sangamo offers training and mentorship programs to help employees grow and advance in their careers. In 2024, Sangamo continued to invest in its employees, recognizing that their talent and dedication are essential to the company’s success. This focus on employee development and inclusion helps Sangamo attract and retain top talent, driving innovation and performance.